Please login to the form below

Not currently logged in
Email:
Password:

Sanofi Pasteur to acquire US biotech

Sanofi Pasteur has announced it is to acquire the US biotech company VaxDesign in a deal worth $60m

Sanofi Pasteur has announced it is to acquire the US biotech company VaxDesign in a deal worth $60m.

Sanofi Pasteur, the vaccines division of sanofi-aventis, will make an upfront payment of $55m upon closing the transaction, with the completion of certain development stages increasing the deal by $5m.

Florida-based VaxDesign is the developer of the Modular IMmune In-vitro Construct (MIMIC) technology – a novel system to combine immunology with engineering to aid research into biological problems.

MIMIC uses data generated in a surrogate human immune system to help determine the selection of optimal product candidates. This surrogate system is intended to be used instead of animal models before studies progress to human clinical trials.

"MIMIC is the most-advanced platform in the field,” said Dr Michel DeWilde, senior vice president, R&D, Sanofi Pasteur. "With this novel model for understanding mechanisms of action, the probability of clinical success increases and the time to market should decrease."

He continued: "MIMIC successfully reproduced our own clinical data and is adaptable for the evaluation of multiple diseases and corresponding patient populations. This platform will provide a significant competitive advantage in the development of vaccines."

28th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics